Invesaro

Stocks Comparison

Myriad Genetics vs Intellia Therapeutics: revenue, profit, margins and growth compared

Myriad Genetics brought in $824.5M of revenue in fiscal 2025, Intellia Therapeutics $67.7M in fiscal 2025. Revenue changed by -1.6% at Myriad Genetics and +16.9% at Intellia Therapeutics on the year before, so Intellia Therapeutics grew faster. Myriad Genetics kept -44.4% of its revenue as net profit, Intellia Therapeutics -609.9%.

Side by side, latest fiscal year

MYGNNTLA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$824.5M$67.7M
Revenue growth-1.6%+16.9%
Net income-$365.9M-$412.7M
Net margin-44.4%-609.9%
Free cash flown/a-$395.9M
Free cash flow marginn/a-585.0%
Earnings per share (diluted)-$3.95-$3.81
Cash$149.6M$155.5M
Debt$119.9Mn/a
Price to earningsn/an/a
Market value$398.9M$1.6B
Dividend yieldn/an/a
Rank by revenue in sector#159 of 523 · Health care#339 of 523 · Health care

Over the years

Revenue
MYGN FY2019: $851.1MMYGN FY2020: $638.6MMYGN FY2020: $557.1MMYGN FY2021: $690.6MMYGN FY2022: $678.4MMYGN FY2023: $753.2MMYGN FY2024: $837.6MMYGN FY2025: $824.5MNTLA FY2018: $30.4MNTLA FY2019: $43.1MNTLA FY2020: $58MNTLA FY2021: $33.1MNTLA FY2022: $52.1MNTLA FY2023: $36.3MNTLA FY2024: $57.9MNTLA FY2025: $67.7MFY18FY19FY20FY21FY22FY23FY24FY25
MYGN $824.5MNTLA $67.7M
Net income
MYGN FY2019: $4.6MMYGN FY2020: -$199.5MMYGN FY2020: -$223.6MMYGN FY2021: -$27.2MMYGN FY2022: -$112MMYGN FY2023: -$263.3MMYGN FY2024: -$127.3MMYGN FY2025: -$365.9MNTLA FY2018: -$85.3MNTLA FY2019: -$474.2MNTLA FY2020: -$134.2MNTLA FY2021: -$267.9MNTLA FY2022: -$474.2MNTLA FY2023: -$481.2MNTLA FY2024: -$519MNTLA FY2025: -$412.7MFY18FY19FY20FY21FY22FY23FY24FY25
MYGN -$365.9MNTLA -$412.7M
Net margin
MYGN FY2019: 0.5%MYGN FY2020: -31.2%MYGN FY2020: -40.1%MYGN FY2021: -3.9%MYGN FY2022: -16.5%MYGN FY2023: -35.0%MYGN FY2024: -15.2%MYGN FY2025: -44.4%NTLA FY2018: -280.4%NTLA FY2019: -1,100.1%NTLA FY2020: -231.5%NTLA FY2021: -810.5%NTLA FY2022: -909.8%NTLA FY2023: -1,326.5%NTLA FY2024: -896.8%NTLA FY2025: -609.9%FY18FY19FY20FY21FY22FY23FY24FY25
MYGN -44.4%NTLA -609.9%
Revenue growth
MYGN FY2020: -25.0%MYGN FY2020: -12.8%MYGN FY2021: +24.0%MYGN FY2022: -1.8%MYGN FY2023: +11.0%MYGN FY2024: +11.2%MYGN FY2025: -1.6%NTLA FY2019: +41.6%NTLA FY2020: +34.5%NTLA FY2021: -43.0%NTLA FY2022: +57.7%NTLA FY2023: -30.4%NTLA FY2024: +59.6%NTLA FY2025: +16.9%FY19FY20FY21FY22FY23FY24FY25
MYGN -1.6%NTLA +16.9%
Free cash flow
MYGN FY2019: $75.1MMYGN FY2020: $50.5MMYGN FY2021: $600KMYGN FY2022: -$151.6MNTLA FY2018: -$67.6MNTLA FY2019: -$110MNTLA FY2020: -$53.5MNTLA FY2021: -$237.8MNTLA FY2022: -$346.8MNTLA FY2023: -$408.1MNTLA FY2024: -$354.7MNTLA FY2025: -$395.9MFY18FY19FY20FY21FY22FY23FY24FY25
MYGN -$151.6MNTLA -$395.9M

Fiscal years as each company reports them; the two may end in different months.

Questions about Myriad Genetics and Intellia Therapeutics

Which is bigger by revenue, Myriad Genetics or Intellia Therapeutics?

Myriad Genetics is bigger by revenue: $824.5M in fiscal 2025, against $67.7M for Intellia Therapeutics in fiscal 2025.

Which keeps more of its revenue as profit, Myriad Genetics or Intellia Therapeutics?

Myriad Genetics had a net margin of -44.4% in fiscal 2025; Intellia Therapeutics had -609.9% in fiscal 2025.

Which grew revenue faster, Myriad Genetics or Intellia Therapeutics?

In their latest fiscal years revenue changed by -1.6% at Myriad Genetics and +16.9% at Intellia Therapeutics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies